Loading…
Loading…
Beiersdorf Aktiengesellschaft (BDRFY) Q2 2026 Earnings Call Transcript
Beiersdorf Aktiengesellschaft ETR: BEI reported a weaker first half of 2026 as continued pressure at NIVEA outweighed growth in its Derma and Healthcare businesses. The company lowered its full-year outlook for its consumer segment and group sales, while outlining an 18-month plan intended to restore NIVEA to sustainable growth.
Nivea-maker Beiersdorf said conflict in the Middle East is disrupting both sales and deliveries in key Gulf markets, highlighting how geopolitical tensions continue to affect consumer-goods companies operating in the region.
Beiersdorf trimmed its guidance on Monday and now expects an organic sales decline in the low-single digit percentage range this year.
Beiersdorf is now fairly valued after a significant decline, with an intrinsic value estimated at €68.85 per share. Recent results show organic growth of 2.4% in 2025, but Q1 2026 saw a 4.6% organic sales decline, with Nivea under particular pressure. Management maintains flat-to-slightly-positive 2026 guidance, citing Derma segment strength and early signs of Nivea recovery, despite analyst skepticism.
Beiersdorf Aktiengesellschaft (BDRFY) Q1 2026 Earnings Call Transcript
Beiersdorf stock's long slump has finally been enough to make one major broker step back from its bearish stance. UBS upgraded the German skincare and consumer-goods group to “neutral” from “sell” on Tuesday.
Beiersdorf remains a global skincare leader, leveraging iconic brands and robust R&D to defend market share. 2025 results showed flat revenue but a 4.5% EPS increase, with disciplined cost control and a strong 4.3 billion EUR net cash position. Management issued a cautious 2026 outlook, disappointing the market, but balance sheet strength supports a 750M EUR share buyback.
No recent filings indexed.